1. Scrip
  2. >>Business

Stockwatch: Dynavax, CoLucid Investors Should Beware The Standard Of Care

 
• By Andy Smith

Dynavax and CoLucid benefited from share price surges last week. But were investors throwing caution to the wind and overlooking the challenges and lessons presented by standard of care therapies? Meanwhile, bluebird bio’s stock soared again.

Dynavax Technologies Corp. saw its stock price climb by about 9% last week, against a drop in the NASDAQ Biotech Index of just just under 1%. In the last gasp of trading that preceded the Labor Day weekend, Dynavax’s announcement of the cancellation of its FDA Advisory Committee meeting for the HEPLISAV-B (recombinant hepatitis B vaccine) BLA had been described by the analysts from Cowen as "rather cryptic" and greeted with about a 30% stock price drop. (Also see "Heplisav-B Review Still On Track Even After Cancelled Advisory Cmte., Dynavax Says" - Pink Sheet, 6 September, 2016.)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

More from Business

Alis Biosciences Launches To Free Cash From Stalled-Out Biotechs

 
• By Mandy Jackson

As investors have begun to ask troubled drug developers to suspend operations and return remaining cash to shareholders, Alis has stepped forward with a new fund aiming to facilitate that.

Top-Selling Drugs 2024: Keytruda, Ozempic And Dupixent Dominate

 
• By Eleanor Malone

Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: Trump’s drug pricing executive order; J&J says taxes, not tariffs, influence US manufacturing; Pfizer discontinuation sparks M&A speculation; US tariffs and manufacturing concentration; and tariffs’ pressures on pharma’s complex supply chain.